T2 Biosystems Receives Nasdaq Extension to Comply with Bid Price Rule; Company to Transfer to Nasdaq Capital Market

Posted: June 13, 2022 at 2:35 am

LEXINGTON, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request for an extension until November 1, 2022, to regain compliance with Nasdaq's minimum bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).

See original here:
T2 Biosystems Receives Nasdaq Extension to Comply with Bid Price Rule; Company to Transfer to Nasdaq Capital Market

Related Posts